Table 3.
Association of pyknons expression levels (high/low) and colorectal patients' clinicopathological and molecular features (n = 73).
| Characteristics | PYK10 | P-value | PYK17 | P-value | PYK42 | P-value | PYK44 | P-value | PYK83 | P-value | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| High | Low | High | Low | High | Low | High | Low | High | Low | ||||||
| Age group | |||||||||||||||
| <68 years | 19 | 23 | 0.325 | 14 | 27 | 0.794 | 15 | 21 | 0.061 | 16 | 22 | 0.801 | 10 | 26 | 1.00 |
| ≥ 68 years | 9 | 19 | 8 | 19 | 5 | 22 | 10 | 16 | 8 | 18 | |||||
| N/A | 3 | 5 | 10 | 9 | 11 | ||||||||||
| Gender | |||||||||||||||
| Female | 9 | 23 | 0.087 | 7 | 25 | 0.119 | 7 | 23 | 0.189 | 9 | 18 | 0.440 | 7 | 20 | 0.780 |
| Male | 19 | 19 | 15 | 21 | 13 | 20 | 17 | 20 | 11 | 24 | |||||
| N/A | 3 | 5 | 10 | 9 | 11 | ||||||||||
| Primary disease site | |||||||||||||||
| Cecum | 0 | 1 | 0.947 | 1 | 0 | 0.621 | 0 | 1 | 0.216 | 1 | 0 | 0.693 | 0 | 1 | 0.187 |
| Descendent colon | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | |||||
| Sigmoid colon | 10 | 15 | 9 | 15 | 9 | 14 | 10 | 13 | 3 | 18 | |||||
| Rectosigmoid junction | 4 | 8 | 3 | 9 | 6 | 6 | 4 | 8 | 6 | 6 | |||||
| Rectum | 14 | 17 | 9 | 21 | 5 | 21 | 11 | 17 | 9 | 18 | |||||
| N/A | 3 | 5 | 10 | 9 | 11 | ||||||||||
| Clinical staging (at diagnosis) | |||||||||||||||
| 0/I | 2 | 13 | 0.085 | 3 | 12 | 0.408 | 3 | 12 | 0.644 | 1 | 13 | 0.016* | 3 | 12 | 0.553 |
| II (a-c) | 17 | 20 | 13 | 22 | 11 | 21 | 18 | 16 | 10 | 23 | |||||
| III (b-c) | 7 | 8 | 6 | 9 | 5 | 9 | 6 | 7 | 5 | 7 | |||||
| IV (b) | 2 | 1 | 0 | 3 | 1 | 1 | 1 | 2 | 0 | 2 | |||||
| N/A | 3 | 5 | 10 | 9 | 11 | ||||||||||
| Primary tumor (T) | |||||||||||||||
| Tis/T1 | 3 | 8 | 0.473 | 2 | 8 | 0.148 | 1 | 9 | 0.227 | 3 | 7 | 0.118 | 1 | 7 | 0.174 |
| T2 | 4 | 10 | 4 | 10 | 4 | 10 | 2 | 11 | 3 | 11 | |||||
| T3 | 17 | 21 | 11 | 26 | 11 | 21 | 18 | 17 | 10 | 24 | |||||
| T4 (a, b) | 4 | 3 | 5 | 2 | 4 | 3 | 3 | 3 | 4 | 2 | |||||
| N/A | 3 | 5 | 10 | 9 | 11 | ||||||||||
| Regional lymph nodes (N) | |||||||||||||||
| N0 | 18 | 31 | 0.278 | 16 | 31 | 1.00 | 31 | 13 | 0.544 | 27 | 18 | 0.783 | 13 | 32 | 0.754 |
| N1/N2 | 10 | 9 | 6 | 13 | 10 | 7 | 10 | 8 | 5 | 10 | |||||
| N/A | 5 | 7 | 12 | 10 | 13 | ||||||||||
| Distant metastasis (M) | |||||||||||||||
| M0 | 26 | 41 | 0.560 | 22 | 43 | 0.546 | 19 | 42 | 0.538 | 25 | 36 | 1.00 | 18 | 42 | 1.00 |
| M1a | 2 | 1 | 0 | 3 | 1 | 1 | 1 | 2 | 0 | 2 | |||||
| N/A | 3 | 5 | 10 | 9 | 11 | ||||||||||
| Histologic grade | |||||||||||||||
| I | 1 | 0 | 0.131 | 1 | 0 | 0.035* | 1 | 0 | 0.249 | 1 | 0 | 0.133 | 0 | 1 | 0.698 |
| II | 24 | 41 | 18 | 45 | 17 | 41 | 22 | 37 | 16 | 41 | |||||
| III | 3 | 1 | 3 | 1 | 2 | 2 | 3 | 1 | 2 | 2 | |||||
| N/A | 3 | 5 | 10 | 9 | 11 | ||||||||||
| Radiotherapy | |||||||||||||||
| Yes | 3 | 4 | 1.00 | 3 | 4 | 0.393 | 0 | 6 | 0.273 | 2 | 3 | 0.489 | 2 | 4 | 0.611 |
| No | 25 | 37 | 19 | 41 | 20 | 36 | 24 | 35 | 16 | 39 | |||||
| N/A | 4 | 6 | 11 | 9 | 12 | ||||||||||
| Adjuvant chemotherapy | |||||||||||||||
| Yes | 14 | 28 | 0.141 | 10 | 16 | 0.594 | 8 | 16 | 1.00 | 14 | 11 | 0.068 | 8 | 15 | 0.567 |
| No | 14 | 13 | 12 | 29 | 12 | 26 | 12 | 27 | 10 | 28 | |||||
| N/A | 4 | 6 | 11 | 9 | 12 | ||||||||||
| MSI status | |||||||||||||||
| MSS+MSI-L | 26 | 39 | 0.281 | 18 | 45 | 0.216 | 18 | 41 | 1.00 | 23 | 37 | 0.557 | 17 | 40 | 0.381 |
| MSH | 0 | 3 | 2 | 1 | 1 | 2 | 2 | 1 | 0 | 3 | |||||
| N/A | 5 | 7 | 11 | 10 | 13 | ||||||||||
| APC mutation | |||||||||||||||
| Yes | 19 | 21 | 0.736 | 14 | 24 | 0.460 | 14 | 22 | 1.00 | 17 | 21 | 0.488 | 11 | 26 | 1.00 |
| No | 4 | 6 | 2 | 8 | 3 | 5 | 3 | 7 | 2 | 7 | |||||
| N/A | 23 | 25 | 29 | 25 | 27 | ||||||||||
| TP53 mutation | |||||||||||||||
| Yes | 20 | 15 | 0.029* | 13 | 20 | 0.322 | 14 | 18 | 0.315 | 16 | 18 | 0.338 | 12 | 20 | 0.072 |
| No | 3 | 12 | 3 | 12 | 3 | 9 | 4 | 10 | 1 | 13 | |||||
| N/A | 23 | 25 | 29 | 25 | 27 | ||||||||||
| KRAS mutation | |||||||||||||||
| Yes | 14 | 22 | 1.00 | 9 | 26 | 0.431 | 8 | 22 | 0.588 | 14 | 24 | 0.195 | 6 | 26 | 0.093 |
| No | 12 | 20 | 11 | 20 | 11 | 21 | 11 | 14 | 11 | 17 | |||||
| N/A | 5 | 7 | 11 | 10 | 13 | ||||||||||
| KRAS mutation | |||||||||||||||
| Yes | 1 | 6 | 0.107 | 1 | 5 | 0.648 | 1 | 4 | 0.634 | 2 | 4 | 1.00 | 1 | 4 | 1.00 |
| No | 22 | 21 | 15 | 27 | 16 | 23 | 18 | 24 | 12 | 29 | |||||
| N/A | 23 | 25 | 29 | 25 | 27 | ||||||||||
| FBXW7 mutation | |||||||||||||||
| Yes | 4 | 1 | 1.67 | 2 | 3 | 1.00 | 3 | 2 | 0.359 | 3 | 2 | 0.636 | 2 | 2 | 0.565 |
| No | 19 | 26 | 14 | 29 | 14 | 25 | 17 | 26 | 11 | 31 | |||||
| N/A | 23 | 25 | 29 | 25 | 27 | ||||||||||
*
N/A, Not available; BRAF mutation: no statistic was calculated since all samples are negative for the mutation. The bold values are the significant values.